公司研究 证 券 研 究 报 告 中复神鹰（688295）2024 年报及 2025 年一季报点评 推荐（维持） 碳纤维阶段性供需失衡，公司产品结构升级 加速推进 事项： 公司发布 2024 年报及 2025 年一季报， 2024 年公司实现营业收入 15.57 亿 元，同比降低 31.07%；归属于上市公司股东的净利润-1.24 亿元，同比转亏。 2025 年第一季度，公司实现营业收入 4.02 亿元，同比降低 10.40%；归母净利 润-0.45 亿元，同比转亏。 评论： [ReportFinancialIndex] 主要财务指标 | | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | | 营业总收入(百万) | 1,557 | 1,944 | 2,464 | 3,398 | | 同比增速(%) | -31.1% | 24.8% | 26.8% | 37.9% | | 归母净利润(百万) | -124 | 65 | 168 | 251 | | 同比增速(%) | -139.1% | 151.9% | 161.2% | 48.9 ...

Investment Rating - The report maintains a "Buy" rating for the company, with a target price of 8.00 CNY based on a 25x PE valuation for 2025 [2][5]. Core Insights - The impact of centralized procurement is gradually clearing, and the company's innovative pipeline is progressing smoothly [1]. - The company has adjusted its revenue and gross margin expectations downward due to the effects of centralized procurement, while overall expense ratios have been adjusted upward [2]. - The company reported a significant decline in revenue and net profit for 2024, primarily due to the implementation of a new round of insulin centralized procurement and inventory control by commercial clients [10]. - Despite the challenges, overseas revenue showed strong growth, with a nearly 80% year-on-year increase in the first quarter of 2025 [10]. - The company is making progress in its research and development pipeline, with positive results from clinical trials for several products [10]. Financial Information Summary - **Revenue Forecast**: The company expects revenues of 2,708 million CNY in 2025, up from 2,010 million CNY in 2024, reflecting a growth rate of 34.7% [4]. - **Net Profit Forecast**: The forecasted net profit for 2025 is 630 million CNY, a significant recovery from a loss of 43 million CNY in 2024 [4]. - **Earnings Per Share**: The expected earnings per share for 2025 is 0.32 CNY, with projections of 0.40 CNY and 0.47 CNY for 2026 and 2027, respectively [4]. - **Gross Margin**: The gross margin is projected to decline slightly from 73.9% in 2024 to 71.8% in 2025 [4]. - **Net Margin**: The net margin is expected to recover to 23.3% in 2025 from a negative margin in 2024 [4].

公司研究 证 券 研 究 报 告 碳纤维阶段性供需失衡，公司产品结构升级 加速推进 事项： 公司发布 2024 年报及 2025 年一季报， 2024 年公司实现营业收入 15.57 亿 元，同比降低 31.07%；归属于上市公司股东的净利润-1.24 亿元，同比转亏。 2025 年第一季度，公司实现营业收入 4.02 亿元，同比降低 10.40%；归母净利 润-0.45 亿元，同比转亏。 评论： [ReportFinancialIndex] 主要财务指标 | | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | | 营业总收入(百万) | 1,557 | 1,944 | 2,464 | 3,398 | | 同比增速(%) | -31.1% | 24.8% | 26.8% | 37.9% | | 归母净利润(百万) | -124 | 65 | 168 | 251 | | 同比增速(%) | -139.1% | 151.9% | 161.2% | 48.9% | | 每股盈利(元) | -0.14 | 0.07 | 0.19 | 0. ...

Investment Rating - The report maintains a "Buy" rating for the company [2][6] Core Views - The company achieved a revenue of 387 million yuan in 2024, representing a year-on-year increase of 8.77%, while the net profit attributable to shareholders decreased by 33.26% to 56 million yuan [3] - The company is expanding its production capacity and successfully advancing its overseas business, with overseas revenue reaching 45 million yuan in 2024, a year-on-year increase of 49.37% [4] - The company is focusing on R&D, with a research and development expense ratio of 12.80% in 2024, and is developing new products to meet the demands of the intelligent robotics sector [5] Financial Performance - The company forecasts revenues of 466 million yuan, 568 million yuan, and 703 million yuan for 2025, 2026, and 2027 respectively, with corresponding net profits of 85 million yuan, 111 million yuan, and 137 million yuan [6][8] - The report indicates a projected EPS of 0.47 yuan, 0.61 yuan, and 0.75 yuan for the years 2025, 2026, and 2027, with P/E ratios of 288, 221, and 179 respectively [6][8] Production and Market Expansion - The company has completed the construction and debugging of its intelligent production line for precision reducers, with plans to gradually increase production capacity in 2025 [4] - The company has acquired assets from the German company Haux, enhancing its sales service coverage [4] Research and Development - The company emphasizes R&D, with a focus on lightweight technology for harmonic reducers, achieving over 30% weight reduction while maintaining output [5] - The company has successfully developed high-precision, high-load, long-life planetary roller screws for humanoid robots [5]

Investment Rating - The report initiates coverage with a "Buy" rating for the company [3][5]. Core Views - The company has successfully expanded its product categories and channels over the past 20 years, focusing on core products and brand development to drive growth [1][3]. - The retail landscape in China is undergoing rapid transformation, with the company effectively leveraging new channel opportunities to enhance operational efficiency and profitability [2][3]. - The company has established a competitive advantage through cost leadership and a robust supply chain, enabling it to maintain high product quality and affordability [3][4]. Summary by Sections Company Development - The company has evolved through three key phases: initial establishment focusing on product diversification, a phase of channel expansion through innovative store formats, and a recent shift towards a multi-channel strategy emphasizing core product branding [13][15]. - From 2017 to 2020, the company launched the "Golden Shop" and "Blue Sapphire" store formats, significantly increasing its market presence and revenue [14][15]. - Since 2021, the company has embraced a full-channel expansion strategy, resulting in substantial revenue growth and improved profitability metrics [15][18]. Channel Expansion - The retail sector is rapidly changing, with a focus on efficiency and the rise of discount formats, which the company has capitalized on through strategic partnerships and channel diversification [2][3]. - The company has achieved notable success in emerging channels such as discount stores and e-commerce platforms like Douyin, enhancing its competitive positioning [2][3]. Product System - The company is focused on building brand recognition for its core products while maintaining a diverse product portfolio to meet evolving consumer demands [3][4]. - The establishment of a cost leadership position through effective supply chain management supports the company's long-term competitive advantage [3][4]. Financial Forecast - The company is projected to achieve significant revenue growth, with estimates of 69.6 billion, 86.3 billion, and 102.4 billion yuan for 2025, 2026, and 2027 respectively, alongside corresponding net profit growth [3][4].

集采影响逐步出清，创新管线进展顺利 ——通化东宝 2024 年报&2025 年一季报点评 核心观点 盈利预测与投资建议 ⚫ 考虑到集采影响，我们下调公司收入与毛利率预期，同时上调整体费用率预期，预 测公司 2025-2027 年每股收益分别为 0.32、0.40、0.47 元（原预测值 2025-2026 年 分别为 0.44/0.58 元），参考可比公司平均市盈率，我们给予公司 2025 年 25 倍 PE 估值，对应目标价 8.00 元，维持"买入"评级。 风险提示 ⚫ 出海进度不达预期风险；新品上市不达预期风险；行业政策变动风险；新兴疗法冲 击风险；地缘政治变化风险等。 公司主要财务信息 | | 2023A | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 营业收入(百万元) | 3,075 | 2,010 | 2,708 | 3,216 | 3,546 | | 同比增长 (%) | 10.7% | -34.7% | 34.7% | 18.8% | 10.3% | | 营业利润(百万元) | 1,365 | ...

输变电设备 金杯电工（002533.SZ） 增持-A(首次) 核心业务保持增长，持续推进产能扩张与全球化布局 2025 年 5 月 23 日 公司研究/公司快报 公司近一年市场表现 事件描述 近日，金杯电工发布 2024 年度报告。2024 年全年，公司实现营业收 入 176.69 亿元，同比增长 15.54%；实现归母净利润 5.69 亿元，同比增长 8.78%。2025 年 Q1，公司实现营业收入 40.97 亿元，同比增长 16.32%。 归母净利润为 1.36 亿元，同比增长 1.84%。 事件点评 市场数据：2025 年 5 月 22 日 收盘价（元）： 9.57 核心业务持续增长，市场份额不断扩张。分业务来看，2024 年电磁线业 务出货量约 8.5 万吨，同比增长约 20%，营收突破 66 亿元，同比增长约 31%， 营收占公司总营收比重接近 40%，利润占比突破 40%。在特高压输变电领域， 公司获得多项特高压项目订单，配套台数同比增长超 20%。在新能源汽车领 域，深化与主流企业合作，拓宽产品应用范围。电线电缆业务 2024 年实现 营收 109.71 亿元，同比增长 8.63%。公司加大直 ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [2][13]. Core Views - The company reported strong performance in 2024, with total revenue reaching 21.81 billion yuan (up 1.7% year-on-year) and net profit attributable to shareholders of 2.94 billion yuan (up 19.5% year-on-year) [4][5]. - The innovative drug segment is accelerating, with significant contributions from various product lines, including raw material intermediates and innovative drugs [5][6]. Financial Performance Summary - In 2024, the company achieved a total revenue of 21.81 billion yuan, with a net profit of 2.94 billion yuan and a non-recurring net profit of 2.90 billion yuan [4]. - For Q1 2025, the company reported a revenue of 4.39 billion yuan (down 29.4% year-on-year) and a net profit of 580 million yuan (down 43.1% year-on-year) [4]. - The company’s major segments, including large-volume infusion, raw material intermediates, and generic drugs, showed stable performance, with notable growth in certain product lines [6]. Segment Performance - The large-volume infusion segment generated sales of 8.91 billion yuan in 2024, despite a decline of 11.85% year-on-year, with a total volume of 4.35 billion bottles/bags [6]. - The non-infusion formulations segment saw a revenue increase of 5.41% year-on-year, reaching 4.17 billion yuan, with significant growth in specific generic products [6]. - The antibiotic intermediates and raw materials segment reported a revenue of 5.86 billion yuan, up 20.9% year-on-year, driven by increased market demand and production efficiency [6]. Innovation and Future Outlook - The successful launch of the innovative drug Jiatailai (Lukangshatuo) is expected to contribute significantly to future revenues, with multiple clinical studies ongoing for various indications [6][13]. - The company anticipates steady performance in its core business and accelerated growth in the innovative drug segment in 2025 [5][13].

Investment Rating - The report maintains a "Buy" rating for the company with a target price of 8.00 CNY, based on a 25x PE valuation for 2025 [2][5]. Core Insights - The impact of centralized procurement is gradually clearing, and the progress of the innovation pipeline is smooth [1]. - The company has adjusted its revenue and gross margin expectations downward due to the effects of centralized procurement, while also raising overall expense ratio expectations [2]. - The company reported a significant decline in revenue and net profit for 2024, primarily due to the implementation of a new round of insulin centralized procurement and inventory control by commercial clients [10]. - However, overseas revenue showed strong growth, with a nearly 80% year-on-year increase in the first quarter of 2025, indicating a recovery in revenue [10]. - The research pipeline is progressing well, with positive results from various clinical trials, including a dual-target inhibitor for gout [10]. Financial Summary - The company’s revenue for 2023 was 3,075 million CNY, with a projected decline to 2,010 million CNY in 2024, followed by a recovery to 2,708 million CNY in 2025 [4]. - The net profit attributable to the parent company is expected to recover from a loss of 43 million CNY in 2024 to 630 million CNY in 2025 [4]. - The gross margin is projected to decrease from 80.1% in 2023 to 71.8% in 2025, while the net margin is expected to improve from -2.1% in 2024 to 23.3% in 2025 [4]. - The earnings per share (EPS) is forecasted to be 0.32 CNY in 2025, up from a loss of 0.02 CNY in 2024 [4].

——一心堂 24 年报及 25 年一季报点评 核心观点 盈利预测与投资建议 行业管理政策变化风险；市场竞争加剧风险；门店扩张带来的盈利能力下滑风险；商誉 占比过高风险等 公司主要财务信息 | | 2023A | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 营业收入(百万元) | 17,380 | 18,000 | 19,512 | 21,476 | 23,919 | | 同比增长 (%) | -0.3% | 3.6% | 8.4% | 10.1% | 11.4% | | 营业利润(百万元) | 786 | 278 | 764 | 980 | 1,105 | | 同比增长 (%) | -36.7% | -64.6% | 174.9% | 28.3% | 12.7% | | 归属母公司净利润(百万元) | 549 | 114 | 594 | 748 | 811 | | 同比增长 (%) | -45.6% | -79.2% | 420.4% | 25.9% | 8.5% | | 每股收益（元） | 0.94 | 0. ...